ECSP066899A - Derivados fenilaminopropanol y métodos de uso - Google Patents

Derivados fenilaminopropanol y métodos de uso

Info

Publication number
ECSP066899A
ECSP066899A EC2006006899A ECSP066899A ECSP066899A EC SP066899 A ECSP066899 A EC SP066899A EC 2006006899 A EC2006006899 A EC 2006006899A EC SP066899 A ECSP066899 A EC SP066899A EC SP066899 A ECSP066899 A EC SP066899A
Authority
EC
Ecuador
Prior art keywords
derivatives
methods
combinations
fibromyalgia
vasomotor symptoms
Prior art date
Application number
EC2006006899A
Other languages
English (en)
Inventor
Puwen Zhang
Eugene Anthony Terefenko
Callain Younghee Kim
An Thien Vu
Stephen Todd Cohn
Eugente John Trybulski
Joseph Peter Sabatucci
Fei Ye
Paige Ering Mahaney
Casey Cameron Mccomas
Michael Anthony Marella
Richard Dale Coghlan
Gavin David Heffernan
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP066899A publication Critical patent/ECSP066899A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se dirige a derivados fenilaminopropanol de fórmula I: o una sal farmacéuticamente aceptable de los mismos, composiciones que contienen estos derivados y los métodos de uso para la prevención y tratamiento de afecciones que mejoran con la recaptación de monoaminas como son, inter alia, los síntomas vasomotores (SVM), la disfunción sexual, trastornos gastrointestinales y genitourinarios, síndrome de fatiga crónica, síndrome de fibromialgia, trastornos del sistema nervioso y combinaciones de las mismas, en particular aquellas afecciones seleccionadas entre el grupo formado por un trastorno depresivo mayor, los síntomas vasomotores, incontinencia urinaria por esfuerzo y por urgencia, fibromialgia, dolor, neuropatía diabética y combinaciones de las mismas.
EC2006006899A 2004-03-30 2006-09-29 Derivados fenilaminopropanol y métodos de uso ECSP066899A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55765104P 2004-03-30 2004-03-30
US56986304P 2004-05-11 2004-05-11
US11/091,885 US7517899B2 (en) 2004-03-30 2005-03-28 Phenylaminopropanol derivatives and methods of their use

Publications (1)

Publication Number Publication Date
ECSP066899A true ECSP066899A (es) 2006-11-24

Family

ID=34964018

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006899A ECSP066899A (es) 2004-03-30 2006-09-29 Derivados fenilaminopropanol y métodos de uso

Country Status (20)

Country Link
US (3) US7517899B2 (es)
EP (1) EP1732887B1 (es)
JP (1) JP2007531751A (es)
KR (1) KR20060134186A (es)
AR (1) AR048675A1 (es)
AT (1) ATE383337T1 (es)
AU (1) AU2005230900A1 (es)
BR (1) BRPI0509390A (es)
CA (1) CA2560967A1 (es)
CR (1) CR8639A (es)
DE (1) DE602005004268T2 (es)
DK (1) DK1732887T3 (es)
EC (1) ECSP066899A (es)
ES (1) ES2299025T3 (es)
IL (1) IL178185A0 (es)
NO (1) NO20064892L (es)
PE (1) PE20060288A1 (es)
PL (1) PL1732887T3 (es)
TW (1) TW200536532A (es)
WO (1) WO2005097744A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
WO2005118539A1 (en) * 2004-06-01 2005-12-15 F.Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor
AU2006242542A1 (en) * 2005-04-29 2006-11-09 Wyeth Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles
US7687529B2 (en) * 2005-09-29 2010-03-30 Wyeth Llc Substituted propylamine derivatives and methods of their use
JP2009510066A (ja) * 2005-09-29 2009-03-12 ワイス 血管運動症状（ｖｍｓ）の治療のためのモノアミン再取り込みのモジュレータである１−（１ｈ−インドール−１−イル）−３−（メチルアミノ）−１−フェニルプロパン−２−オール誘導体および関連の化合物
BRPI0619263A2 (pt) * 2005-11-30 2011-09-27 Hoffmann La Roche indóis de 3-amino-1-arilpropila e indóis aza-substituìdos, métodos para prepará-los, composição farmacêutica e uso dos referidos indóis
CA2632284A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 3-amino-2-arylpropyl azaindoles and uses thereof
CA2631048A1 (en) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag Methods for synthesis of 3-amino-1-arylpropyl indoles
CL2007002449A1 (es) * 2006-08-24 2008-03-07 Wyeth Corp Compuestos derivados de indolinona fenilaminopropanol; composicion farmaceutica; procedimiento de preparacion de dichos compuestos, utiles en disfuncion sexual, trastornos gastrointestinales y genitourinarios, fibromialgia, fatiga cronica, trastornos
US7671238B2 (en) * 2006-10-04 2010-03-02 Wyeth Llc Arylamino-arylpropanolamine derivatives and methods of their use
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
EP2665707B1 (en) * 2011-01-20 2017-01-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
EP2875013B1 (en) * 2012-07-17 2017-11-29 Glaxosmithkline Intellectual Property (No. 2) Limited Indolecarbonitriles as selective androgen receptor modulators
KR101460738B1 (ko) * 2012-08-23 2014-11-12 한국과학기술연구원 신규한 2-나프틸 프로판-2-올 화합물, 이를 포함하는 약학 조성물, 및 상기 약학 조성물을 포함하는 제제
JOP20200344A1 (ar) 2018-07-03 2020-12-31 Univ Illinois منشطات لاستجابة البروتين غير المطوي
US20220296604A1 (en) * 2019-08-08 2022-09-22 New York University Indole compounds as modulators of rage activity and uses thereof
CN114539080A (zh) * 2022-03-02 2022-05-27 八叶草健康产业研究院(厦门)有限公司 一种2-(2-氨基-6-氯苯基)-乙酸钠的制备方法
WO2024158872A1 (en) * 2023-01-25 2024-08-02 The Rockefeller University 1,3-indole-propanamide inhibitors of sars-cov-2 plpro/nsp3 and derivatives thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454554A (en) 1960-10-14 1969-07-08 Colgate Palmolive Co Aminoalkyliminodibenzyl compounds
US4123543A (en) 1971-09-16 1978-10-31 Ab Kabi Derivatives of substituted indoline lactans with effect on the central nervous system
CS175831B1 (es) 1974-12-17 1977-05-31
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4310524A (en) 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
PH18686A (en) 1981-05-26 1985-08-29 Merck & Co Inc 1-(3 halo-2-pyridinyl) piperazine
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
EP0135905A3 (de) 1983-09-29 1986-10-22 ASTA Pharma Aktiengesellschaft Neue 1-(Alkyl-hydroxy-phenyl)-1-hydroxy-2-(alkylamino)-propane
CA1280421C (en) 1985-07-02 1991-02-19 Albert A. Carr 1,4-disubstituted piperidinyl derivatives
ZA885824B (en) 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
US4826844A (en) 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
CA2083698C (en) 1990-06-01 1997-11-04 Albert A. Carr (+)-alpha-(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US5648511A (en) 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5502047A (en) 1993-03-22 1996-03-26 Kavey; Neil B. Treatment for insomnia
US5516774A (en) 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2714378B1 (fr) 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
AU3414295A (en) 1994-08-19 1996-03-14 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
AU5857296A (en) 1995-05-17 1996-11-29 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
GB9606016D0 (en) 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
UA48219C2 (uk) 1996-03-25 2002-08-15 Елі Ліллі Енд Компані Композиція для вгамування болю (варіанти) та спосіб вгамування болю
WO1998014208A1 (en) 1996-09-30 1998-04-09 President And Fellows Of Harvard College Reactive ligands and covalent ligand-protein complexes
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2321648A1 (en) 1998-03-02 1999-09-10 Hunter Heath Iii Fluoxetine hydrochloride for decreasing hot flashes
TW528754B (en) 1998-04-29 2003-04-21 Wyeth Corp Indolyl derivatibes as serotonergic agents
WO2000002551A2 (en) 1998-07-13 2000-01-20 Nps Pharmaceuticals, Inc. Methods and compounds for treating depression
PL350924A1 (en) 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
DE60035232T2 (de) 1999-07-01 2008-02-14 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von chronischem Müdigkeits-Syndrom
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804115B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
EP1272483A2 (en) 2000-03-24 2003-01-08 Millenium Pharmaceuticals, Inc. OXINDOLE INHIBITORS OF FACTOR Xa
US20030008860A1 (en) 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
GB2362826A (en) 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
AU9087301A (en) 2000-09-11 2002-03-26 Sepracor Inc Ligands for monoamine receptors and transporters, and methods of use thereof
DE60221642T3 (de) 2001-02-12 2017-10-26 Wyeth LLC (n.d.Ges.d. Staates Delaware) O-desmethyl-venlafaxine succinat salz
CA2442410A1 (en) 2001-03-29 2002-10-10 Owen Brendan Wallace Duloxetine for treatment of hot flashes
EP1266659A1 (en) 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
WO2003010169A1 (en) 2001-07-25 2003-02-06 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7, 8-dihydro-6h-5-oxa-1-aza-phenanthrene
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003037334A1 (en) 2001-10-31 2003-05-08 Merck & Co., Inc. Method for treating or preventing symptoms of hormonal variation including hot flashes
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
JP2005526079A (ja) 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
TW200402289A (en) 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
BR0313411A (pt) 2002-08-14 2005-06-28 Pharmacia & Upjohn Co Llc Uso de reboxetina para o tratamento de ondas de calor
US7345096B2 (en) 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040152710A1 (en) 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7524846B2 (en) * 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7491723B2 (en) * 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7419980B2 (en) * 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US20050130987A1 (en) 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7531543B2 (en) * 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7365076B2 (en) * 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US20050165082A1 (en) * 2003-12-16 2005-07-28 Wyeth Methods of treating vasomotor symptoms
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use

Also Published As

Publication number Publication date
EP1732887B1 (en) 2008-01-09
JP2007531751A (ja) 2007-11-08
PE20060288A1 (es) 2006-05-23
DK1732887T3 (da) 2008-04-28
ES2299025T3 (es) 2008-05-16
EP1732887A1 (en) 2006-12-20
KR20060134186A (ko) 2006-12-27
CA2560967A1 (en) 2005-10-20
IL178185A0 (en) 2006-12-31
NO20064892L (no) 2006-12-13
AU2005230900A1 (en) 2005-10-20
BRPI0509390A (pt) 2007-09-18
US20090093469A1 (en) 2009-04-09
TW200536532A (en) 2005-11-16
DE602005004268T2 (de) 2009-01-02
ATE383337T1 (de) 2008-01-15
DE602005004268D1 (de) 2008-02-21
PL1732887T3 (pl) 2008-05-30
AR048675A1 (es) 2006-05-17
US20050222148A1 (en) 2005-10-06
WO2005097744A1 (en) 2005-10-20
US7517899B2 (en) 2009-04-14
CR8639A (es) 2007-06-08
US20090099164A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
ECSP066899A (es) Derivados fenilaminopropanol y métodos de uso
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
PE20090154A1 (es) Metodos para tratar y monitorear el tratamiento de transtornos asociados con il-13
EA201200406A1 (ru) Соединения и композиции, которые являются модуляторами активности tlr
CL2008002916A1 (es) Compuestos derivados de triazolopiridina, inhibidores 11-beta-hidroxiesteroide deshidrogenasa tipo i; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion de la diabetes, dislipidemia, obesidad, entre otros.
DOP2012000246A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
GT200000019A (es) Inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc.
CR10866A (es) Derivados de aril sulfamida y metodos para su uso
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
PA8615001A1 (es) Derivados n-heterociclo sustituidos y metodos de uso de los mismos
CL2017000382A1 (es) Compuestos bicíclicos sustituidos
PA8628101A1 (es) Derivados fenilaminopropanol y metodos de uso
ECSP088300A (es) Derivados de benzotiadiazolilfenilalquilamina para uso en el tratamiento de condiciones mejoradas por la retoma de monoamina
GT200500332A (es) Azabenzoxazoles para el tratamiento de trastornos del snc
PA8615201A1 (es) Derivados arilo fusionados y heteroarilo y metodos de uso de los mismos
BRPI0415292A (pt) derivados de alcanol e cicloalcanol-amina e métodos para seu uso
BRPI0415380A (pt) derivados aril ciclo alcanol substituìdos e processos de seus usos
BRPI0415410A (pt) derivados de arilalquil-e cicloalquilalquil-piperazina e métodos de seu uso
PA8628001A1 (es) Derivados fenilaminopropanol y metodos de uso
NI200600091A (es) Derivados n-heterociclo sustituidos y metodos de uso de los mismos
AR045314A1 (es) Composiciones farmaceuticas de analepticos y antidepresivos
SV2005002067A (es) Derivados fenilaminopropanol y metodos de uso ref. 305179
GT200600439A (es) Derivados de propilamina sustituida y metodos para su utilización
PA8615101A1 (es) Derivados arilo cicloalcanol sustituidos y metodos de uso de los mismos
BRPI0415478A (pt) derivados de fenilpiperazina cicloalcanol e métodos de seu uso